Divergent Levels of Marker Chromosomes in an hiPSC-Based Model of Psychosis by TCW, Julia et al.
Divergent Levels of Marker Chromosomes
in an hiPSC-Based Model of Psychosis
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation TCW, J., C. M. Carvalho, B. Yuan, S. Gu, A. N. Altheimer, S.
McCarthy, D. Malhotra, et al. 2017. “Divergent Levels of Marker
Chromosomes in an hiPSC-Based Model of Psychosis.” Stem Cell




Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions





Divergent Levels of Marker Chromosomes in an hiPSC-Based Model
of Psychosis
Julia TCW,1,2 Claudia M.B. Carvalho,3,* Bo Yuan,3 Shen Gu,3 Alyssa N. Altheimer,1,2 Shane McCarthy,4
Dheeraj Malhotra,5 Jonathan Sebat,6 Arthur J. Siegel,10,11 Uwe Rudolph,12,13 James R. Lupski,3,7,8,9
Deborah L. Levy,13,14,* and Kristen J. Brennand1,2,15,*
1Departments of Neuroscience
2Friedman Brain Institute
Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA
3Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
4Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA
5F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland
6Departments of Psychiatry, Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA
7Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA
8Texas Children’s Hospital, Houston, TX 77030, USA
9Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
10Department of Internal Medicine, McLean Hospital, Belmont, MA 02478, USA
11Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
12Laboratory of Genetic Neuropharmacology, McLean Hospital, Belmont, MA 02478, USA
13Department of Psychiatry, Harvard Medical School, Boston, MA 02115, USA
14Psychology Research Laboratory, McLean Hospital, Belmont, MA 02478, USA
15Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA
*Correspondence: cfonseca@bcm.edu (C.M.B.C.), dlevy@mclean.harvard.edu (D.L.L.), kristen.brennand@mssm.edu (K.J.B.)
http://dx.doi.org/10.1016/j.stemcr.2017.01.010
SUMMARY
In the process of generating presumably clonal human induced pluripotent stem cells (hiPSCs) from two carriers of a complex structural
rearrangement, each having a psychotic disorder, we also serendipitously generated isogenic non-carrier control hiPSCs, finding that the
rearrangement occurs as an extrachromosomal marker (mar) element. All confirmed carrier hiPSCs and differentiated neural progenitor
cell lines were found to be mosaic. We caution that mar elements may be difficult to functionally evaluate in hiPSC cultures using
currently available methods, as it is difficult to distinguish cells with and without mar elements in live mosaic cultures.
INTRODUCTION
Chromosomal trisomy disorders have long been associated
with abnormal developmental outcomes (Oster-Granite,
1986). While early studies detected large chromosomal ab-
normalities via karyotype analysis or fluorescence in situ
hybridization (FISH), more recently, genomic approaches
have facilitated unbiased identification of microdeletions
and microduplications (reviewed in Watson et al., 2014),
identifying many that are significantly associated with
schizophrenia and bipolar disorder (CNV and Schizo-
phreniaWorkingGroups of the Psychiatric Genomics Con-
sortium and Psychosis Endophenotypes International
Consortium, 2016; Malhotra et al., 2011). Human induced
pluripotent stemcell (hiPSC)-basedmodels are an emerging
strategy by which to evaluate the functional effects of such
chromosomal aberrations in human neurons.
Growing evidence suggests that hiPSCs are fundamen-
tally similar regardless of reprogramming methods (Choi
et al., 2015; Schlaeger et al., 2015) or donor cell types (Kyt-
tala et al., 2016) and that reprogramming increases the
number of genes with a detectable donor effect in disease
models (Thomas et al., 2015). Mitochondrial heteroplasmy
(Perales-Clemente et al., 2016), genetic (Gore et al., 2011;
Hussein et al., 2011; Liu et al., 2014), and epigenetic (Me-
khoubad et al., 2012; Nazor et al., 2012) differences all
contribute to intra-individual variability between hiPSCs.
While genetic errors likely reflect both pre-existing muta-
tions in the source somatic cells (Abyzov et al., 2012; Young
et al., 2012) and the stresses associatedwith cellular replica-
tion (Laurent et al., 2011; Lu et al., 2014), epigenetic aberra-
tions occur in hiPSCs regardless of the somatic cell type of
origin and likely arise during the reprogramming process
(Ma et al., 2014). Genetic and epigenetic errors can distin-
guish hiPSC lines from the same individual. Since suchmu-
tations are assumed to arise at equal frequency in hiPSCs
reprogrammed from cases and controls, they are not typi-
cally considered serious impediments to disease-modeling
studies if multiple hiPSC lines are used in comparisons.
Although hiPSC-based models are generally assumed to
capture the genetic variants contributing to a disease
state, notable exceptions have been reported. First, not
only can trisomy correction be facilitated by selecting
against a transgene (TKNEO) targeted to one copy of
chromosome 21 (chr 21) (Li et al., 2012), but spontaneous
derivation of isogenic controls can also occur in Down
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Figure 1. Identification of 9p24.1 DUP/TRP and a Mar Chromosome in Two Patients with Psychotic Disorders
(A) Schematic of human chr 9, highlighting band 9p24.1, which contains the DUP/TRP region. Encoded genes are listed on the right; genes
in the DUP region (red) and TRP region (blue) are indicated (GLDC is in the TRP region).
(legend continued on next page)
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syndrome trisomy21hiPSCs (Weick et al., 2013). Second, in
hiPSCs derived from a patient withMiller-Dieker syndrome
(MDS; MIM #247200), patient fibroblasts lost an abnormal
ring chr 17 during hiPSC derivation and duplicated the
wild-type homolog, apparently via a compensatory unipa-
rental disomy mechanism (Bershteyn et al., 2014).
We present evidence that although extrachromosomal
marker (mar) elements are relatively stable during extended
culture of mosaic patient-derived fibroblasts, instability
during the reprogramming process led to the derivation
of isogenic non-carrier hiPSC lines as well as mosaic carrier
hiPSC lines. Because this mutation was initially identified
as a complex genomic rearrangement (CGR), rather than
as a karyotypic abnormality, it represents a cautionary indi-
cation that the precise structure of any genetic mutation
should be clarified before moving forward with hiPSC-
based studies.
RESULTS
Identification of a Duplication/Triplication of 9p24.1
in Two Patients with Psychotic Disorders
A small family cohort was identified in which a CGR
involving chr 9p24.1 occurred in two carriers, one with a
diagnosis of schizoaffective disorder (DL3363, proband)
and one with a diagnosis of bipolar disorder with psychotic
features (DL5459, mother) (Figure 1); there were also two
clinically unaffected non-carrier relatives (full brother and
maternal half-sister of the proband) (Figure 1C). This
9p24.1 CGR is constituted by a duplication (DUP) of 1.18
Mb (comprising 12 genes) followed by a triplicated (TRP)
segment of 0.672 Mb (comprising three genes: UHRF2,
GLDC, and part of KDM4C) (Figure 1A). Originally identi-
fied by array comparative genomic hybridization (aCGH)
(Malhotra et al., 2011), it was more fully characterized by
custom high-resolution aCGH as a CGR involving 9p24.1
(Figure 1B) (unpublished data).
The 9p24.1 DUP/TRP Exists on aMarker Chromosome
Human fibroblasts (HFs) were obtained from the two
9p24.1 DUP/TRP carriers; unexpectedly, G-band chromo-
somal karyotyping identified mosaicism for an abnormal
mar element (DL3363, 56.2%; DL55459, 25.0%) (Figures
1D and 1E; Table S1). Mar elements are structurally
abnormal (and typically small) chromosomes that cannot
be resolved by conventional banding cytogenetics alone;
their clinical significance varies depending on the specific
genetic material (ISCN, 2013). Because karyotypic mosai-
cism can underestimate the prevalence of the mar element
(false negatives occur due to the small size of the mar
element), these results were confirmed by FISH in inter-
phase cells for a probe to glycine decarboxylase (GLDC), a
gene included in the 9p24.1 TRP region. FISH analysis indi-
cated that in both carriers the mar element contained se-
quences from the 9p24.1 region, and also confirmed that
HF lines from both carriers contain a similar level of mar
mosaicism (55% ± 0.5%) (Figures 1F and 1G; Table S1).
Mar elements are often believed to have low stability, as
they can be lost during cell division due to their small
size. However, when we compared the frequency of the
mar by FISH for GLDC in 9p24.1-carrier HFs at low (p5)
(DL3363, 55.0%; DL5459, 54.5%) and high (p20) passage
(DL3363, 54.0%; DL5459, 45.5%), we found only minimal
decline in extra FISH signals for the GLDC locus in inter-
phase cells (Figure 1G and Table S1).
Reprogramming of 9p24.1-Carrier HFs Yields Isogenic
Carrier and Non-carrier hiPSCs; 9p24.1-Carrier hiPSCs
Show Variable Mosaicism in All Lines
We generated genetically unmanipulated and presum-
ably clonal hiPSCs from the two 9p24.1 carriers (Figures 2
and 3) and the two non-carrier relatives (data not shown)
using Sendai viral vectors to reprogram subject HFs, as
described previously (Topol et al., 2016). All hiPSCs
showed robust self-renewal as well as mRNA and protein
expression of NANOG, OCT4, TRA-1-81, and TRA-1-60
(Figures 2A, 2B, S2A, and S2B). Validated hiPSCs were
identical to their original fibroblasts by DNA finger-
printing (Figures S2F and S2G). At least three validated
hiPSCs were generated per person; moreover, three
9p24.1-carrier and three isogenic 9p24.1-non-carrier
hiPSCs were derived from both 9p24.1 carriers’ HFs
and confirmed by PCR and/or aCGH (Figures 2C and
(B) From leukocytes, custom aCGH identified a CGR in the proband DL3363 (shown) and mother DL5459. This structural rearrangement,
constituted by a DUP/TRP, spans 1.85 Mb.
(C) List of HF lines used in this study.
(D and E) Karyotype analysis of HF lines derived from the 9p24.1-carrier proband (DL3363) and mother (DL5459). Representative karyotype
images ofmar (M) (D) and percentagemosaicism (E) ofHF lines derived from the 9p24.1-carrier proband (DL3363) andmother (DL5459). Red
arrows indicate an additional t(1;18)(p22;q11.2) abnormality identified in 3/20 fibroblast cells (but not present in validated hiPSC lines).
(F and G) GLDC FISH analysis of HF lines derived from the 9p24.1-carrier proband (DL3363) and mother (DL5459). FISH images
(6003magnification, images cropped and resized post capture) (F) from HFs from the proband (DL3363) (shown) and his mother (DL5459)
with two (top), three (middle), and four (bottom) GLDC probes (red) within the DAPI-positive nucleus. Proportion of HF cells (G) with GLDC
FISH probes in early passage (p5) and late passage (p20) from DL3363 and DL5459 (number of cells = 200 each, one assay per line).
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S2C–S2E). Karyotyping of 9p24.1 hiPSCs detected a high
frequency of mar elements in otherwise karyotypically
normal lines (Figure 2D and Table S2). PCR of one of the
CGR breakpoint junctions confirmed that mar-positive
hiPSCs were carriers of the 9p24.1 rearrangement; in
contrast, the CGR was not present in mar-negative hiPSCs;
this mosaic pattern was maintained throughout hiPSC
passaging from low passage (p3) to higher passage (p10)
in both mar-positive and mar-negative lines (Figures S2C
and S2D).
We analyzed hiPSCs from both the proband (DL3363)
and mother (DL5459) for the percentage presence of
the mar element. Although presumably clonal in origin,
9p24.1-positive hiPSCs possessed varying levels (10%–
60%) of the mar element, typically below the rate detected
in the source HFs (Figure 2E and Table S2). There was
no noticeable difference in hiPSC morphology between
isogenic high mar (60%), low mar (10%), and non-carrier
(no mar) hiPSCs (0%) (Figures 2A and 2F).
Mar Element Contains Sequence of Chr 9 and the
Triplicated Gene GLDC
FISH in interphase cells confirmed that 9p24.1-carrier
hiPSCs from both the proband (DL3363) and mother
(DL5459) showed evidence of cells with two (left) or three
(right) chr 9 signals (within the DAPI-positive nuclei) (Fig-
ure 3A). Moreover, additional FISH images demonstrated
overlap of the chr 9 signal with themar element, indicating
that the mar is likely the source of the chr 9 DUP/TRP
sequence (Figure 3C). The percentage of mosaicism in
two genotype-positive hiPSCs, one with high mar and
one with low mar mosaicism, by G-banding karyotype
analysis at p12 (DL3363 C1, 10%; DL5459 C5, 55%), was
comparable with the level of mosaicism determined by
FISH at p12 (DL3363C1, 6.5%;DL5459C5, 49.0%), despite
being tested 6–12 months apart (Figure 3B and Table S3).
When we compared the frequency of mosaicism in high
and low mar hiPSCs by GLDC FISH at p12 (DL5459
C5 [high mar], 44.0%; DL5459 C6 [low mar], 32.5%),
following extended culture (p22) (DL5459 C5 [high mar],
42.5%; DL5459 C6 [low mar], 20.5%), we found variable
decline in evidence of extra FISH signals in interphase cells
for the GLDC locus (Figures 3D and 3E; Tables S3 and S4).
Consistent with chr 9 FISH signal in the mar element
(Figure 3C), FISH analysis also demonstrated overlap of
the GLDC signal with the mar element (Figure 3F).
Perhaps reflecting the low expression of GLDC in HFs
relative to NPCs, qPCR for GLDC expression detected
significantly increased GLDC levels in only one carrier HF
(DL3363) compared with a non-carrier relative (DL6463)
(Figure S1B). GLDC levels in hiPSCs (from both 9p24.1-car-
rier and isogenicnon-carrier lines derived fromDL3363 and
DL5459) were significantly higher than in HFs (p = 0.0004
for DL3363 and p = 0.0002 for DL5459) (Figure 3G). While
we observed a significant increase in GLDC expression in
three 9p24.1-carrier hiPSCs from DL5459 relative to three
isogenic non-carrier hiPSCs (p = 0.004), there was consider-
able variability inGLDC expression among DL3363 hiPSCs
independent of carrier status (Figure 3G).
Neural Differentiation of 9p24.1 High and Low Mar
hiPSCs Can Yield NPCs with Similar Levels of Mar
Elements
We tested the effect of neural differentiation on the fre-
quency ofmarmosaicism.Whenwe comparedNPCs differ-
entiated from p15 high and low mar hiPSCs as determined
by karyotyping at p12 (DL5459 C5 [high mar], 55.0%;
DL5459C6 [lowmar], 10.0%), therewere no obvious differ-
enceswith respect toNPC cellularmorphology or detection
of NPCmarkers such as FOXP2, NESTIN, and PAX6 (Figures
4A and 4B). Interestingly, the percentage of mosaicism in
carrier high and low mar hiPSC NPCs, evaluated by GLDC
FISH, was similar (35% ± 2.5%) but differed from source
hiPSCs (high mar, 55.0%; low mar, 10.0%), suggesting
that the level of mosaicism in NPCs did not reflect the
source hiPSCs (Figures 4C and 4D; Table S2).
DISCUSSION
Mar elements are rare in the general population (estimated
to occur in 0.044% of newborn infants) (Liehr et al., 2004),
Figure 2. Serendipitous Generation of 9p24.1-Positive and 9p24.1-Negative hiPSCs from Two 9p24.1-Carrier Patients
(A and B) Validation of hiPSCs derived from the 9p24.1-carrier proband (DL3363) and mother (DL5459). Immunofluorescence for NANOG,
OCT4, TRA1-81, and TRA-1-60 (A) and fluorescence-activated cell sorting histograms for TRA-1-60 and SSEA4 (B) from hiPSCs derived from
the 9p24.1-carrier proband (DL3363) and mother (DL5459). Scale bar, 200 mm. Representative images per condition are selected from
Figure S2A.
(C) Representative Agilent aCGH plots of the 9p24.1 region reveals the presence of the DUP/TRP rearrangement in some hiPSCs (9p24.1-
positive) generated from the proband but not in others (9p24.1-negative isogenic hiPSCs).
(D and E) Karyotype analysis of hiPSCs derived from the 9p24.1-carrier proband (DL3363) and mother (DL5459). Representative karyotype
images of mar (M) (D) and percentage mosaicism (E) of hiPSCs derived from the 9p24.1-carrier proband (DL3363) and mother (DL5459).
Karyotype counts indicated variable levels of mosaicism of the mar element in all genotype-positive hiPSCs.
(F) Bright-field images of high mar (60%) and low mar (10%) 9p24.1-carrier hiPSCs. Scale bar, 200 mm.
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but >30% mar element carriers are clinically abnormal
(Liehr et al., 2006) and mar elements are enriched approx-
imately 7-fold in patients with developmental delay
(0.288% of cases) (Liehr andWeise, 2007). The size, genetic
content, and extent of somaticmosaicism contribute to the
clinical impact of a mar carrier case (Liehr et al., 2013).
Somatic mosaicism is present in slightly more than 50%
of mar carriers, and the extent of mosaicism can range
from very low (<0.5%) to very high (>95%); nonetheless,
it is difficult to directly correlate the extent of mosaicism
to the magnitude of the clinical phenotype, likely because
only one tissue is typically evaluated (Liehr et al., 2013).
The mitotic stability of mar elements in vitro is dependent
on their shape and telomeres (Hussein et al., 2014).
Whether the 9p24.1 mar element described here affects
the clinical phenotypes in these two carriers is unknown;
the mosaicism in presumably clonal hiPSCs has made it
difficult to functionally evaluate the causal impact of this
mar element.
As future hiPSC-based studies include a growing number
of patients with rare CGRs, they are likely to include indi-
viduals with mar elements; we recommend that the pre-
cise structure of novel CGRs be clarified by karyotyping
before moving forward with hiPSC-based studies. Our
work suggests that although mar elements can be main-
tained with relative stability in mosaic proliferating HF
populations, they are frequently lost during the reprog-
ramming process. More critically, the extent of mosaicism
in patient HFs and hiPSCs is not particularly predictive
of the extent of mosaicism present in patient-derived
NPCs. While the generation of spontaneous isogenic car-
rier and non-carrier hiPSCs from the same patients is fortu-
itous, the difficulty resolving carrier status in individual
living cells makes these hiPSCs a difficult platform for mo-
lecular and cellular phenotyping in disease-modeling
studies.
Instability of chromosomal abnormalities has been well
documented in vivo and in vitro. Among practicing clinical
geneticists, it is widely understood that mar elements are
unstable and likely to present as mosaic in vivo (Liehr
et al., 2010). Similarly, trisomies found early in pregnancy
during chorionic villus studies may undergo ‘‘trisomy-to-
disomy’’ rescue via uniparental disomy (Spence et al.,
1988). Moreover, high rates of aneuploidy in source cells
do not always translate into similarly high rates in the
derived hiPSCs, likely because aneuploidies may be sub-
jected to selective pressures during reprogramming, result-
ing in different levels of tolerance in the reprogramming
cells (Hamada et al., 2012).
The presence of mar mosaicism in source HFs, presum-
ably clonal hiPSCs and hiPSC NPCs, indicates that these
lines will not be readily amenable to functional evaluation
via in vitromodeling using currentmethods, as one cannot
distinguish 9p24.1 and control cells in live cultures. Stan-
dard phenotypic comparisons in these variably mosaic
lines would be expected to yield large inter-experiment
and intra-individual variation, requiring comparisons of
increased numbers of cells and/or biological replicates to
reach statistically significant conclusions. While pheno-
typic assays could theoretically be combinedwith stringent
molecular techniques to resolve the 9p24.1 status of
individual neural cells, combining post hoc FISH with
many standard hiPSC-based assays of neuronal function
(dendritic branching, synaptic imaging, multi-electrode
array [MEA], electrophysiology, neurotransmitter release)
and/or global transcriptomic, proteomic, or epigenetic
approaches would likely prove practically difficult. FISH
sample processing methodologies may be technically diffi-
cult to pair with some sensitive synaptic staining protocols,
many commercial MEA plates are not amenable to imag-
ing, and post hoc FISH would dramatically reduce the
throughput of dendritic tracing or electrophysiological
comparisons, approaches already limited by the small
number of cells that can be evaluated. For population-
wide studies, from neurotransmitter release to ‘‘-omics’’ ap-
proaches, each experiment would have to be normalized to
reflect the current extent of mosaicism in each culture,
dramatically confounding already variable analyses.
Figure 3. In 9p24.1-Carrier hiPSCs, the Mar Contains Sequence of Chr 9 and the Triplicated Gene GLDC
(A–C) Chr 9 FISH analysis of hiPSCs from the 9p24.1-carrier proband (DL3363) and mother (DL5459). FISH images (6003 magnification,
images cropped and resized post capture) (A) with two (left) or three (right) chr 9 probes (red) within the DAPI-positive nucleus as well as
approximate correlation (B) between karyotypic mar mosaicism and chr 9 FISH mosaicism. FISH image (6003 magnification, image
cropped and resized post capture) (C) from a 9p24.1-carrier hiPSC showing overlap of the chr 9 probe with the mar element (arrow).
(D–F) GLDC FISH analysis of hiPSCs derived from the 9p24.1-carrier proband (DL3363) and mother (DL5459). FISH images (6003
magnification, images cropped and resized post capture) (D) and quantitative analysis (number of cells = 200 each, one assay per line)
(E) from high mar and low mar of 9p24.1-carrier (C1–C3) and non-carrier (NC1–NC3) hiPSCs at low (p12) and high (p24) passage with three
(left) and four (right) GLDC probes (red) within the DAPI-positive nucleus. FISH image (6003 magnification, image cropped and resized
post capture) (F) from 9p24.1-carrier hiPSCs showing overlap of the GLDC probe with the mar element (arrow). C, carrier; NC, non-carrier.
(G) qRT-PCR for GLDC mRNA levels in HFs as well as carrier and non-carrier hiPSCs from the 9p24.1-carrier proband (DL3363) and mother
(DL5459). Percentages of mar in each cell line are indicated. Data are shown as mean ± SD from three technical replicates of each in-
dividual line. One-way ANOVA with Tukey’s multiple comparison test: n.s., not significant; **p < 0.01, ***p < 0.001.
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The reversion of the mutation to wild-type may reflect a
selection disadvantage to 9p24.1 cells in vitro, particularly
during the process of reprogramming and neural differenti-
ation; however, our inability to distinguish and/or purify
9p24.1 and control fibroblasts, or to repeatedly obtain
skin biopsies from these two individuals, makes this a diffi-
cult hypothesis to test.We present this cautionary evidence
of a heritable but unstable genetic mutation to alert hiPSC
researchers to the possibility that some genetic variations
may be particularly intransigent to hiPSC-based modeling
at the present time. Thus, confirmation of the presence of
the genetic variant in source HFs, clonal hiPSCs, and differ-
entiated cells is essential prior to beginning phenotypic
characterizations.
Figure 4. Neural Differentiation of 9p24.1 High and Low Mar hiPSCs Yields Similar Levels of Mar Elements
(A and B) Bright-field (A) and immunofluorescence for FOXP2, NESTIN, and PAX6 (B) images of NPCs from high (55.0%) and low mar
(10.0%) 9p24.1-carrier hiPSCs (DL5459 C5 and C6, respectively). Scale bars, 500 mm.
(C and D) FISH images (6003magnification, images cropped and resized post capture) (C) and quantitative analysis (number of cells = 200
each, one assay per line) (D) from NPCs differentiated from high (55.0%) and low mar (10.0%) 9p24.1-carrier hiPSCs (DL5459 C5 and
DL5459 C6) with three (left) and four (right) GLDC probes (red) within the DAPI-positive nucleus.
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EXPERIMENTAL PROCEDURES
Patients, hiPSC Derivation, and NPC Differentiation
Human subjects work was approved by the McLean Hospital Insti-
tutional Review Board. HFs were expanded from skin biopsies and
hiPSCs were derived using Sendai viral vectors (Life Technologies).
NPCs were generated using the 7-day neural induction protocol
(Life Technologies). See Supplemental Experimental Procedures
for detailed descriptions of cohort, HF culture, hiPSC derivation,
and NPC differentiation protocols.
Molecular Analysis
aCGH was conducted using a custom 4 3 180 K microarray (Agi-
lent Technologies); genotypes were confirmed by long-range
PCR. Karyotyping and FISH were performed by Wicell Cytoge-
netics (Madison, WI). See Supplemental Experimental Procedures
for detailed descriptions of aCGH, karyotype, FISH, PCR, DNA
fingerprinting, and immunocytochemical techniques.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and four tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2017.
01.010.
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